- Global patents for innovative formulations and drug delivery platforms
- Strong development pipeline for cannabinoid-based pharmaceutical and nutraceutical products
- Capabilities to manufacture products of a quality unmatched by other industry players
Canadian biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) continues to strengthen its position in the cannabis industry through the development of its patent-protected bio-cannabis products. The company’s current initiatives are geared toward the manufacture and commercialization of its product pipeline in anticipation of cannabis legalization in Canada, the United States and other regulated international markets.
Pivot’s unique approach incorporates the acquisition of disruptive drug formulation and delivery technologies for use in the development of innovative bio-cannabis products. The company places a high premium on producing sustainable quality products, a focus that many other enterprises in the cannabis space lack. Through its proprietary drug delivery platforms, Pivot is able to develop high quality, industry-leading cannabinoid-based therapeutic products for the pharmaceutical and nutraceutical markets.
Pivot’s wholly owned subsidiary, Pivot Green Stream Health Solutions Inc. (“PGS”), is responsible for the research, development and commercialization of the company’s products. PGS has acquired global rights for several patented technologies, including BiPhasix™ transdermal drug delivery, Solmic oral solubilization, Thrudermic transdermal nanotechnology and Ready-to-Infuse-Cannabis (RTIC) powder-to-oil technology.
These proprietary technologies are deployed in the development of cannabidiol (CBD) and tetrahydrocannabinol (THC) based products. Pivot’s cannabinoid pipeline of pharmaceutical products includes two that use the Solmic drug delivery technology for cancer supportive care, targeting the relief of mucositis and chemotherapy-induced nausea and vomiting. The company has also deployed its Bi-Phasix™ delivery platform for the development of four products that target women’s sexual desire disorder, glaucoma, dysmenorrhea and dermatological conditions. Pivot’s development pipeline also contains products for the relief of restless leg syndrome, opioid withdrawal and the treatment of pain and inflammation.
The company’s Bi-Phasix™ drug delivery platform has been tested in human trials approved by both the FDA and EMA. This system has been proven to enhance the bioavailability of drugs and improve clinical outcomes. Apart from its focus on the pharmaceutical space, PGS is developing several CBD-based natural health products for the nutraceutical market, with the aim of acquiring the Natural Health Product (NHP) designation from Health Canada. This will enhance the marketability of these products, which require a shorter development cycle and offer opportunities for faster revenue generation.
In a recent product development update, Pivot announced that the development of its 1% CBD-based Oral Micelle Solution, in collaboration with the company’s German technology partner, Solmic GmbH, is complete, and the product is ready for market. This formulation employs Pivot’s patented delivery system to produce two topical creams to treat a variety of medical indications, most notably chemotherapy-induced nausea and vomiting.
The company’s patented formulations and drug delivery technologies have positioned it to assume a leading position in the cannabis industry. Pivot has the capabilities to generate products that will be unequalled in quality by any other licensed producer or product distributor. Global protection of its patents will enable the company to capitalize on international markets, establish a strong market position and deliver higher value for its shareholders.
For more information, visit the company’s website at www.PivotPharma.com
More from CanadianCannabisWire
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CanadianCannabisWire.com